MOXR 0916

Drug Profile

MOXR 0916

Alternative Names: MOXR0916; RG 7888

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Phase Unknown Urogenital cancer

Most Recent Events

  • 20 Jan 2017 Genentech plans a phase II trial for Urogenital cancer (First-line therapy, Late-stage disease, Metastatic disease, Combination therapy) (IV) (NCT03029832)
  • 18 Jan 2017 Investigation in Urogenital cancer in USA (IV) before January 2017
  • 16 Apr 2016 Preliminary efficacy, safety and pharmacokinetics data from a phase I trial in Solid tumours was presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top